Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. The company is currently 100% long-term debt-free and has sufficient reserves to meet future requirements. Identified CapEx projects include a specialty chemicals plant with an expected CapEx of ₹20-30 crores. Additional CapEx relates to an ongoing EC application project and land acquisition for future projects. No specific plans for raising funds via debt or equity have been disclosed; expansions and CapEx are planned to be funded through existing resources.

Any current/future capex/capital investment/strategic investment?

Specialty chemical plant CapEx expected between ₹20-30 crores; product details undisclosed due to secrecy agreements. Another project with Environment Clearance (EC) application filed and under process, involving additional CapEx. Land acquisition underway for future projects; a 20-acre land bank identified for upcoming expansions. Ongoing R&D focused on Polyacrylamide solid product development, with plant setup planned post R&D completion by fiscal year-end. Company actively strengthening team and R&D capabilities to support current and new product innovation. Always exploring new m

Future growth expectations in sales/revenue/volumes?

The company expects substantial growth in sales during the current quarter, particularly for the Polyacrylamide solid product as R&D progresses and the plant setup is imminent. Strong support and good allocation from principals are driving higher demand in the domestic chemical distribution business, leading to increased sales volume and profitability. Export volumes from the US oil and gas sector remain steady, with efforts to expand the product portfolio and customer base aimed at boosting sales further. An increase in market share is anticipated in both local and export markets, parti

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects substantial sales growth in the current quarter, especially for Polyacrylamide solid as R&D progresses and plant setup begins. Improved market share and increased export volumes are anticipated due to easing logistics and better support from principals. Newer and more robust binder products will aid in expanding the customer base and boosting volumes. Chemical distribution business is experiencing higher volumes and realizations, driving up margins and profitability. Stable raw material prices and good market reach support improved realizations and profitability in

IN US

Sale is live|00:00:00left today

Black Rose Industries LtdQ2 FY24Chemicals & Petrochemicals

Black Rose Industries Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹90.2P/E: 21.8Market Cap: ₹491 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company expects substantial growth in sales during the current quarter, particularly for the Polyacrylamide solid product as R&D progresses and the plant setup is imminent.
→Strong support and good allocation from principals are driving higher demand in the domestic chemical distribution business, leading to increased sales volume and profitability.
→Export volumes from the US oil and gas sector remain steady, with efforts to expand the product portfolio and customer base aimed at boosting sales further.
→An increase in market share is anticipated in both local and export markets, particularly for Acrylamide liquid and solid products.
→The introduction of newer, more robust binder versions and ongoing trials of Polyacrylate based dispersants are expected to enhance acceptance and volumes in the Polyacrylamide liquid segment.
→The company is actively pursuing new projects, acquisitions of land for future expansion, and setting up new manufacturing units as opportunities arise.

Margin guidance

Category 3

→The company expects substantial sales growth in the current quarter, especially for Polyacrylamide solid as R&D progresses and plant setup begins.
→Improved market share and increased export volumes are anticipated due to easing logistics and better support from principals.
→Newer and more robust binder products will aid in expanding the customer base and boosting volumes.
→Chemical distribution business is experiencing higher volumes and realizations, driving up margins and profitability.
→Stable raw material prices and good market reach support improved realizations and profitability in Acrylamide products.
→The company is debt-free with sufficient reserves, enabling investment in future growth projects and CapEx.
→Continuous efforts in R&D, product portfolio expansion, and team strength enhancement are expected to accelerate growth.
→Overall, the company foresees healthy EBITDA and PAT growth consistent with business progress.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the transcript.
→The company is currently 100% long-term debt-free and has sufficient reserves to meet future requirements.
→Identified CapEx projects include a specialty chemicals plant with an expected CapEx of ₹20-30 crores.
→Additional CapEx relates to an ongoing EC application project and land acquisition for future projects.
→No specific plans for raising funds via debt or equity have been disclosed; expansions and CapEx are planned to be funded through existing resources.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders in specific terms. However, relevant insights can be summarized as follows: - The company is experiencing strong support and good allocation from its principals, aiding in catering to higher domestic market demand. - Export business, especially in the US oil and gas sector, is steady and the company is working to expand product portfolios and add new customers. - There were some rollovers in Acrylamide liquid export orders due to logistics issues and high freight costs. - The company is gaining market share, building stronger client relationships, and continuously looking to add new products and enter new markets. - The pipeline includes a specialty chemical plant under development, with CapEx of ₹20-30 crores, though product details remain confidential. - Overall, management expects substantial growth in sales and export volumes, reflecting a positive outlook on future orders.

Capex plans

Yes

→Specialty chemical plant CapEx expected between ₹20-30 crores; product details undisclosed due to secrecy agreements.
→Another project with Environment Clearance (EC) application filed and under process, involving additional CapEx.
→Land acquisition underway for future projects; a 20-acre land bank identified for upcoming expansions.
→Ongoing R&D focused on Polyacrylamide solid product development, with plant setup planned post R&D completion by fiscal year-end.
→Company actively strengthening team and R&D capabilities to support current and new product innovation.
→Always exploring new manufacturing opportunities in collaboration with principals, with potential future CapEx allocations accordingly.

How does Black Rose Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Black Rose Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Black Rose Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio